STX - Ticker AI Digest

Shield Therapeutics plc
9.43 | Today 0.75%
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (STX) 0
No same-day market news for STX on 2026-04-15.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 1
STX 08:23
Shield Therapeutics plc
Publication of Report, Reinforcing FDA Approval
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Shield Therapeutics plc announces the publication of an independent peer-reviewed report in *Pediatric Drugs*, reinforcing the FDAs approval of ACCRUFeR®/FeRACCRU® (ferric maltol) for treating iron deficiency in pediatric patients aged 10 and over. The report highlights positive results from the Phase 3 FORTIS/ST10-01-305 trial, confirming the drugs efficacy, safety, and tolerability in children. This milestone underscores the importance of addressing underdiagnosed iron deficiency in children and expands the drugs market potential. ACCRUFeR®/FeRACCRU® is now the leading branded prescription oral iron, addressing a significant unmet medical need globally.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
STX 11:31
Shield Therapeutics plc
Audited results for year ended 31 December 2025
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Shield Therapeutics PLC reported strong financial results for 2025, with net revenues and other income reaching $49.7 million, driven by a 56% growth in ACCRUFeR® net revenues to $45.8 million. The company achieved positive cash flow in Q4 2025 and expects to deliver an operating profit in 2026. Key highlights include
ACCRUFeR® becoming the #1 branded prescription oral iron in the US, with ~199,000 prescriptions dispensed and a 21% increase in average net selling price.
Expansion of global patient access through regulatory approvals and partnerships in Canada, South Korea, China, and Japan.
Reduced loss for the year to $17.7 million, compared to $27.2 million in 2024, due to revenue growth and disciplined expense management.
Strengthened balance sheet with cash and cash equivalents of $11.6 million as of December 31, 2025, and amended debt terms providing increased financial flexibility.
Anticipated strong growth in 2026, driven by continued ACCRUFeR® sales momentum, international expansion, and disciplined financial management.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 4
STX 11:31
Shield Therapeutics plc
Audited results for year ended 31 December 2025
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Shield Therapeutics PLC reported strong financial results for 2025, with net revenues and other income reaching $49.7 million, driven by a 56% growth in ACCRUFeR® net revenues to $45.8 million. The company achieved positive cash flow in Q4 2025 and expects to deliver an operating profit in 2026. Key highlights include
ACCRUFeR® becoming the #1 branded prescription oral iron in the US, with ~199,000 prescriptions dispensed and a 21% increase in average net selling price.
Expansion of global patient access through regulatory approvals and partnerships in Canada, South Korea, China, and Japan.
Reduced loss for the year to $17.7 million, compared to $27.2 million in 2024, due to revenue growth and disciplined expense management.
Strengthened balance sheet with cash and cash equivalents of $11.6 million as of December 31, 2025, and amended debt terms providing increased financial flexibility.
Anticipated strong growth in 2026, driven by continued ACCRUFeR® sales momentum, international expansion, and disciplined financial management.
STX 08:23
Shield Therapeutics plc
Publication of Report, Reinforcing FDA Approval
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Shield Therapeutics plc announces the publication of an independent peer-reviewed report in *Pediatric Drugs*, reinforcing the FDAs approval of ACCRUFeR®/FeRACCRU® (ferric maltol) for treating iron deficiency in pediatric patients aged 10 and over. The report highlights positive results from the Phase 3 FORTIS/ST10-01-305 trial, confirming the drugs efficacy, safety, and tolerability in children. This milestone underscores the importance of addressing underdiagnosed iron deficiency in children and expands the drugs market potential. ACCRUFeR®/FeRACCRU® is now the leading branded prescription oral iron, addressing a significant unmet medical need globally.
STX 06:04
Shield Therapeutics plc
Total Voting Rights
STX 06:01
Shield Therapeutics plc
EMA approves extension - to include adolescents

AI Crunch

Single-Ticker AI Crunch
STX signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Shield Therapeutics plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full STX AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for STX on 2026-04-15.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
100003960
Enterprise Value
21404362
Public Float
26.34
Broker Target
17.333
Shares Out
1068418471
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BYV81293
Market
LSE - AIM
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-22
Net Debt
18520745.0
Cash
11625232.0
EPS
-0.01
Net Income
-18025406.0
Revenue
50743741.0
Enterprise Value
21404362
Trailing PE
-
Forward PE
65.3595
Price Sales TTM
2.0121
Price Book MRQ
76.3287
EV Revenue
3.079
EV EBITDA
-1.4946

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
1068418471
Public Hands
26.34
Institutions
-
Institutions As Of
-
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
0
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
0
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

AI Charts is armed for the next catalyst in STX.

No same-day headline has printed on 2026-04-15 yet, but the latest digestion is ready below the chart workflow and the catalyst beacons can still map the recent tape.
Standby Tape Data 2026-04-15 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
0 Today
Catalyst Pulse
Waiting for a fresh same-day headline while recent digestion stays on deck.
06:04 Latest Tape Total Voting Rights
AI Charts Studio
STX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-04-15 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast